Mathematical Models to Explore Potential Effects of Supersaturation and Precipitation on Oral Bioavailability of Poorly Soluble Drugs

Poorly soluble drugs are increasingly formulated into supersaturating drug delivery systems which may precipitate during oral delivery. The link between in vitro drug concentration profiles and oral bioavailability is under intense investigation. The objective of the present work was to develop closed-form analytical solutions that relate in vitro concentration profiles to the amount of drug absorbed using several alternate assumptions and only six parameters. Three parameters define the key features of the in vitro drug concentration-time profile. An additional three parameters focus on physiological parameters. Absorption models were developed based on alternate assumptions; the drug concentration in the intestinal fluid: (1) peaks at the same time and concentration as in vitro, (2) peaks at the same time as in vitro, or (3) reaches the same peak concentration as in vitro. The three assumptions provide very different calculated values of bioavailability. Using Case 2 assumptions, bioavailability enhancement was found to be less than proportional to in silico examples of dissolution enhancement. Case 3 assumptions lead to bioavailability enhancements that are more than proportional to dissolution enhancements. Using Case 1 predicts drug absorption amounts that fall in between Case 2 and 3. The equations developed based on the alternate assumptions can be used to quickly evaluate the potential improvement in bioavailability due to intentional alteration of the in vitro drug concentration vs. time curve by reformulation. These equations may be useful in making decisions as to whether reformulation is expected to provide sufficient bioavailability enhancement to justify the effort.

[1]  M. Brewster,et al.  Evaluation of gastrointestinal drug supersaturation and precipitation: strategies and issues. , 2013, International journal of pharmaceutics.

[2]  Harsh Chauhan,et al.  Correlating the behavior of polymers in solution as precipitation inhibitor to its amorphous stabilization ability in solid dispersions. , 2013, Journal of pharmaceutical sciences.

[3]  Po-Chang Chiang,et al.  Systemic concentrations can limit the oral absorption of poorly soluble drugs: an investigation of non-sink permeation using physiologically based pharmacokinetic modeling. , 2013, Molecular pharmaceutics.

[4]  L. S. Taylor,et al.  Liquid–Liquid Phase Separation in Highly Supersaturated Aqueous Solutions of Poorly Water-Soluble Drugs: Implications for Solubility Enhancing Formulations , 2013 .

[5]  James D. Litster,et al.  Quantitative analysis of the inhibitory effect of HPMC on felodipine crystallization kinetics using population balance modeling , 2013 .

[6]  P. Annaert,et al.  Drug precipitation-permeation interplay: supersaturation in an absorptive environment. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[7]  R. Bogner,et al.  Solution-mediated phase transformation: significance during dissolution and implications for bioavailability. , 2012, Journal of pharmaceutical sciences.

[8]  A. Dokoumetzidis,et al.  Elucidating the Role of Dose in the Biopharmaceutics Classification of Drugs: The Concepts of Critical Dose, Effective In Vivo Solubility, and Dose-Dependent BCS , 2012, Pharmaceutical Research.

[9]  Alfred Fahr,et al.  Drug delivery strategies for poorly water-soluble drugs: the industrial perspective , 2011, Expert opinion on drug delivery.

[10]  Stefan Willmann,et al.  An update on computational oral absorption simulation , 2011, Expert opinion on drug metabolism & toxicology.

[11]  M. Pikal,et al.  Solubility advantage of amorphous pharmaceuticals, part 3: Is maximum solubility advantage experimentally attainable and sustainable? , 2011, Journal of pharmaceutical sciences.

[12]  R. Bogner,et al.  Solution-Mediated Phase Transformation of Haloperidol Mesylate in the Presence of Sodium Lauryl Sulfate , 2011, AAPS PharmSciTech.

[13]  Michael J. Pikal,et al.  Solubility Advantage of Amorphous Pharmaceuticals: II. Application of Quantitative Thermodynamic Relationships for Prediction of Solubility Enhancement in Structurally Diverse Insoluble Pharmaceuticals , 2010, Pharmaceutical Research.

[14]  Na Sun,et al.  Dissolution rate and apparent solubility of poorly soluble drugs in biorelevant dissolution media. , 2010, Molecular pharmaceutics.

[15]  R. Bogner,et al.  Crystallization of amorphous indomethacin during dissolution: effect of processing and annealing. , 2010, Molecular pharmaceutics.

[16]  John J Totman,et al.  Postprandial changes in small bowel water content in healthy subjects and patients with irritable bowel syndrome. , 2010, Gastroenterology.

[17]  Lynne S. Taylor,et al.  Understanding the Behavior of Amorphous Pharmaceutical Systems during Dissolution , 2010, Pharmaceutical Research.

[18]  Patrick Augustijns,et al.  Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? , 2009, Journal of pharmaceutical sciences.

[19]  Steven C. Sutton,et al.  Role of Physiological Intestinal Water in Oral Absorption , 2009, The AAPS Journal.

[20]  Sebastian Polak,et al.  Population-Based Mechanistic Prediction of Oral Drug Absorption , 2009, The AAPS Journal.

[21]  Emma L. McConnell,et al.  Meal-Induced Acceleration of Tablet Transit Through the Human Small Intestine , 2009, Pharmaceutical Research.

[22]  A. Basit,et al.  Gut instincts: explorations in intestinal physiology and drug delivery. , 2008, International journal of pharmaceutics.

[23]  J. Dressman,et al.  Dissolution Media Simulating Conditions in the Proximal Human Gastrointestinal Tract: An Update , 2008, Pharmaceutical Research.

[24]  H Lennernäs,et al.  Intestinal permeability and its relevance for absorption and elimination , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[25]  A. Dokoumetzidis,et al.  Predictive models for oral drug absorption: from in silico methods to integrated dynamical models , 2007, Expert opinion on drug metabolism & toxicology.

[26]  N. Hosten,et al.  Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging , 2005, Alimentary pharmacology & therapeutics.

[27]  Panos Macheras,et al.  Identification of Biowaivers Among Class II Drugs: Theoretical Justification and Practical Examples , 2004, Pharmaceutical Research.

[28]  N. Rodríguez-Hornedo,et al.  Surfactant-facilitated crystallization of dihydrate carbamazepine during dissolution of anhydrous polymorph. , 2004, Journal of pharmaceutical sciences.

[29]  Shobha N. Bhattachar,et al.  Dissolution Behavior of a Poorly Water Soluble Compound in the Presence of Tween 80 , 2003, Pharmaceutical Research.

[30]  Panos Macheras,et al.  A Population Growth Model of Dissolution , 1997, Pharmaceutical Research.

[31]  Kevin C. Johnson,et al.  Guidance in the Setting of Drug Particle Size Specifications to Minimize Variability in Absorption , 1996, Pharmaceutical Research.

[32]  Hsiu-Ying Yu,et al.  Analysis of Tissue Distribution of Valproate in Guinea-Pigs: Evidence for Its Capacity-Limited Tissue Distribution , 1995, Pharmaceutical Research.

[33]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[34]  Gordon L. Amidon,et al.  Estimating the Fraction Dose Absorbed from Suspensions of Poorly Soluble Compounds in Humans: A Mathematical Model , 1993, Pharmaceutical Research.

[35]  Patrick J. Sinko,et al.  Predicting Fraction Dose Absorbed in Humans Using a Macroscopic Mass Balance Approach , 1991, Pharmaceutical Research.

[36]  Aditya Mohan Kaushal,et al.  Amorphous drug delivery systems: molecular aspects, design, and performance. , 2004, Critical reviews in therapeutic drug carrier systems.

[37]  Christos Reppas,et al.  Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms , 2004, Pharmaceutical Research.

[38]  Kevin C. Johnson,et al.  Dissolution and Absorption Modeling: Model Expansion to Simulate the Effects of Precipitation, Water Absorption, Longitudinally Changing Intestinal Permeability, and Controlled Release on Drug Absorption , 2003, Drug development and industrial pharmacy.

[39]  J. Dressman,et al.  In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[40]  W. Curatolo,et al.  Physical chemical properties of oral drug candidates in the discovery and exploratory development settings , 1998 .

[41]  Lawrence X. Yu,et al.  Compartmental transit and dispersion model analysis of small intestinal transit flow in humans , 1996 .

[42]  G L Amidon,et al.  Novel approach to the analysis of in vitro-in vivo relationships. , 1996, Journal of pharmaceutical sciences.

[43]  G L Amidon,et al.  Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. , 1996, Advanced drug delivery reviews.

[44]  P. Macheras,et al.  Toward a quantitative approach for the prediction of the fraction of dose absorbed using the absorption potential concept. , 1989, Biopharmaceutics & drug disposition.

[45]  J. Dressman,et al.  Mixing-tank model for predicting dissolution rate control or oral absorption. , 1986, Journal of pharmaceutical sciences.

[46]  G. Amidon,et al.  Absorption potential: estimating the fraction absorbed for orally administered compounds. , 1985, Journal of pharmaceutical sciences.

[47]  G. Amidon,et al.  Physicochemical model for dose-dependent drug absorption. , 1984, Journal of pharmaceutical sciences.

[48]  B. C. Goodacre,et al.  A MATHEMATICAL MODEL OF DRUG ABSORPTION , 1981, Journal of clinical and hospital pharmacy.